Abstract
Multiple myeloma (MM) is a malignant tumor originating from plasma cells, and in recent years, its incidence has shown a significant upward trend in our country. Venous thromboembolism (VTE) is a relatively common complication in multiple myeloma (MM) patients. Venous thromboembolism includes deep vein thrombosis (DVT) and pulmonary embolism (PE), with patients facing a high risk of DVT during treatment. Studies have shown that the procoagulant state of MM, inflammatory response, and the therapeutic drugs used significantly increase the incidence of DVT. However, the exact mechanisms behind the increased risk of venous thrombosis are not yet fully understood. The occurrence of DVT not only has a severely negative impact on patient survival rates but also leads to adjustments in treatment plans and a reduction in patients' quality of life. This article analyzes the relationship between risk factors for DVT and MM, exploring current diagnostic methods, risk assessment tools, and personalized preventive treatment strategies, ultimately proposing future research directions. Through a review and analysis of relevant literature, it aims to enhance the understanding of multiple myeloma and deep vein thrombosis, providing references for clinical diagnosis and treatment.